Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Liver, Pancreas and Biliary Tract

Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: A prospective single center study

Massimo Iavarone, Giulia Tossetti, Flavia Facchetti, Matilde Topa, Joey Ming Er, Shou Kit Hang, Debora Licari, Andrea Lombardi, Roberta D’Ambrosio, Elisabetta Degasperi, Alessandro Loglio, Chiara Oggoni, Riccardo Perbellini, Riccardo Caccia, Alessandra Bandera, Andrea Gori, Ferruccio Ceriotti, Luigia Scudeller, Antonio Bertoletti, Pietro Lampertico

A R T I C L E   I N F O

Article history:
Received 21 June 2022
Accepted 12 September 2022
Available online xxx

Keywords:
SARS-CoV-2
Hepatitis B
Hepatitis C
Portal hypertension
Hepatocellular carcinoma
Spike-proteins
Nucleocapsid-protein
Pfizer-BioNTech BNT162b2
Moderna mRNA-1273

A B S T R A C T

Background and Aims: COVID-19 mRNA vaccines were approved to prevent severe forms of the disease, but their immunogenicity and safety in cirrhosis is poorly known.

Method: In this prospective single-center study enrolling patients with cirrhosis undergoing COVID-19 vaccination (BNT162b2 and mRNA-1273), we assessed humoral and cellular responses vs healthy controls, the incidence of breakthrough infections and adverse events (AEs). Antibodies against spike- and nucleocapsid-protein (anti-S and anti-N) and Spike-specific T-cells responses were quantified at baseline, 21 days after the first and second doses and during follow-up.

Results: 182 cirrhotics (85% SARS-CoV-2-naïve) and 38 controls were enrolled. After 2 doses of vaccine, anti-S titres were significantly lower in cirrhosis vs controls [1,751 (0.4–25,000) U/mL vs 4,523 (250–25,000) U/mL, p=0.012] and in SARS-CoV-2-naïve vs previously infected cirrhosis [999 (0.4–17,329) U/mL vs 7,500 (12.5–25,000) U/mL, p=0.001]. T-cell responses in cirrhosis were similar to controls, although with different kinetics. In SARS-CoV-2-naïve cirrhotics, HCC, Child-Pugh B/C and BNT162b2 were independent predictors of low response. Neither unexpected nor severe AEs emerged. During follow-up, 2% turned SARS-CoV-2 positive, all asymptomatic.

Conclusion: Humoral response to COVID-19 vaccines appeared suboptimal in patients with cirrhosis, particularly in SARS-CoV-2-naïve decompensated cirrhosis, although cellular response appeared preserved, and low breakthrough infections rate was registered.

© 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

1. Introduction

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represented one of the worst pandemics in history and is still ongoing worldwide [1]. It has been shown that patients with cirrhosis, and particularly those with a more advanced disease and comorbidities, have worse outcomes for COVID-19 [2–4]. Vaccination has been shown to be one of the most effective ways not
only to control SARS-CoV-2 pandemic but also to reduce hospitalization rates, major complications, and deaths [5–7]. With these premises, scientific societies have recommended priority vaccination of these vulnerable patients [8,9]. However, despite the inclusion of over 100,000 participants in the phase 3 trials, data in patients with chronic liver disease are limited, as these patients represent less than 0.5% of those enrolled [5–7]. The evaluation of efficacy and safety of vaccination in patients with cirrhosis is important not only for the severity of COVID-19 in these patients but also because the immune response to COVID-19 vaccination might be dampened, as it has previously shown with vaccines against S. pneumoniae, influenza and hepatitis B virus [10–12]. A few preliminary data on COVID-19 vaccination in patients with chronic liver disease, cirrhosis and liver transplant suggested a suboptimal antibody response [13–15]. However, these studies have several limitations: lack of healthy control group; the enrolment of only few patients with compensated and decompensated cirrhosis and none with hepatocellular carcinoma (HCC), a short post-vaccination follow-up, no information on post-vaccination infection rate and durability of response.

In addition, no studies have assessed so far, the specific anti-Spike T-cell response in patients with cirrhosis undergoing vaccination. While tests for antibodies are routinely performed, the technical complexity of SARS-CoV-2-specific T-cell measurements has so far limited this analysis. The rapid tests based on release of T-cells cytokines like IFN-gamma and IL-2 in the supernatants of whole blood pulsed with peptides covering immunogenic regions of Spike could represent a reliable approach to evaluate quantity and function of vaccine-induced Spike specific T-cells [16].

The present study aimed to assess the immunogenicity, incidence of breakthrough infections, and safety of COVID-19 mRNA vaccines through 180 days from first dose in patients with compensated and decompensated cirrhosis with different aetiologies, compared to healthy subjects.

2. Patients and methods

2.1. Study design

This is a prospective, single-center, pharmacological observational study including all patients with cirrhosis of any etiology followed in our center who agreed to receive COVID-19 vaccination. The study is part of an hospital-based protocol, the Pollimmune-COVID study (#286_2021), started on Jan 25th, 2021, after the approval of the INMI “Lazzaro Spallanzani” Ethics Committee (Roma, Italy).

The primary endpoint of the study was the immunogenicity of COVID-19 mRNA vaccines (BNT162b2 Pfizer BioNTech or mRNA-1273Moderna), measured as SARS-CoV-2 anti-Spike protein antibodies (anti-S) titres after 21 days from the second dose and predictors of response (V2). Secondary endpoints were durability of humoral response to COVID-19 vaccines measured at different time-points; evaluation of T-cell responses in a subgroup of patients and controls at different time-points; predictors of humoral response; evaluation of incidence and severity of post-vaccination SARS-CoV-2 infections in patients with cirrhosis; and safety defined by the incidence and grade of adverse events following vaccination.

All subjects gave their written consent to participate to the study which was carried out in conformity with the 2013 revision of the Declaration of Helsinki.

2.2. Patients and healthy controls

From March 2021, Italy prioritized immunization with COVID-19 vaccines of patients with chronic diseases, including those with cirrhosis. Patients with history of COVID-19 within 3–6 months before availability of vaccine might have received either a single dose or two doses according to physician decision, while all the others received 2 doses of vaccine. The study design also included a control group of healthcare workers who received COVID-19 mRNA vaccines with no major co-morbidities, unmatched for age, gender prevalence and previous COVID-19.

Patients and controls were also stratified according to the history of previous COVID-19 (either by a known diagnosis by nasopharyngeal swab for SARS-CoV-2 by PCR before enrolment or a positive result at baseline for antibodies against SARS-CoV-2 nucleocapsid protein (anti-N). Exclusion criteria included age <18 years and inability to provide informed consent.

2.3. Patients’ information

Clinical data was obtained from patients’ medical records and routine blood tests up to 3 months prior to the date of the first vaccination. Liver function was evaluated by means of both biochemical [i.e. bilirubin, international normalized ratio (INR), albumin, creatinine] and clinical variables (i.e. presence and degree of ascites, encephalopathy, esophageal varices). For each patient Child-Pugh and the Model for End-Stage Liver Disease (MELD) scores were assessed with last available data. Data on immunosuppressive drugs, HCC and comorbidities were also collected. Participants filled in a questionnaire on vaccination side effects after 7 days following first and second doses: local (pain, redness, swelling, and lymphadenopathy) and systemic (fever, chills, headache, fatigue, myalgia, arthralgia, nausea and vomiting, diarrhea) adverse events (AE) were reported and graded according to the Common Terminology Criteria for AEs (CTCAE) grade scale. Any other adverse events occurring thereafter, or any other event or positivity for SARS-CoV-2 to the nasopharyngeal swab or any hospitalizations for COVID-19 were collected during normal visits and reported.

2.4. Humoral response

The anti-S titres were quantified by the anti–SARS-CoV-2 S enzyme immunoassay (Roche Elecsys, Roche, Monza) that tests for antibodies against the receptor-binding domain of the SARS-CoV-2 spike protein. According to Manufacturer’s instruction, the antibody-positive cut-off was 0.8 U/mL. A low positive response was defined from 0.8 to 100 U/mL, based on thresholds of validating studies and on cut-offs used in previous trials. The anti-N antibodies (Roche Diagnostics, Monza; the antibody-positive cut-off was 0.08 Cut-off Index) were quantified at the same time-points to either confirm or detect SARS-CoV-2 infections in both patients and controls. Both tests were performed on Cobas e801 automatic analyzer (Roche Diagnostics, Monza, Italy) by ECLIA.

Blood samples were taken 1–3 days before the first dose (V0, Fig. 1), 21 days after the first dose of vaccine (V1) and 21 days after the second dose (V2). A pre-planned fourth test at 180 days from the second dose was anticipated before the third dose of vaccine (V3), due to change in vaccination policy in Italy [133 (70–208) days].

2.5. Spike-specific T cellular response

The spike-specific T-cell response was analyzed by a cytokine release assay (CRA) of whole peripheral blood stimulated using a SARS-CoV-2 spike-derived 15-mer peptides (S) pool described previously, that covers the immunogenic regions of SARS-CoV-2 Spike protein and represents 41% of the whole Spike protein [16,17]. Freshly drawn whole blood (320μL; within 6 h since venipuncture) was mixed with 80μL RPMI and stimulated with S
pool peptides to a final peptide concentration of 2 μg/mL or mixed with an equivalent amount of DMSO as control. Culture supernatants were collected 16 h after culture and stored at −80 °C until cytokine quantification. IFN-γ/IL-2 concentrations in plasma were quantified using an Ella machine (ProteinSimple) with microfluidic multiplex cartridges following the manufacturer’s instructions. Background cytokine levels quantified from DMSO controls were subtracted from the corresponding peptide pool stimulated samples. The threshold for a positive response was set at 10 times the lower limit of quantification for each cytokine (IFN-γ = 1.7 pg/mL; IL-2 = 5.4 pg/mL).

Whole blood collected before (Day 0), 10 and 21 days after the first dose and 21 (day 42), 39 (day 60) and 133 days after the second dose were used for these analyses.

2.6. Statistical analysis

Data is displayed as median (range) for continuous variables and as number and percentage for categorical variables. For categorical variables, the Chi-Square statistic was used to assess the statistical significance between groups. Continuous variables were first tested for normal distribution using the Kolmogorov-Smirnov test and Q-Q plots and then compared by t-test if normally distributed or by Kruskal Wallis/Mann-Whitney test if non-normally distributed. Patients and controls were stratified according to previous SARS-CoV-2 infection (anti-N positivity at baseline sample); patients were stratified according to liver function (according to Child-Pugh classification and MELD score), anti-S levels after first dose and presence of HCC and immunosuppressive drugs. Interval regression models were fitted to take into account left- and right-censored anti-S titres due to limits of essay detection, in both univariable and multivariable models. Factors putatively associated to anti-S titres were initially selected based on their clinical significance; to obtain a parsimonious model, the AIC criterion was used to select the best fitting multivariable model. Models for repeated measures within patient were applied whenever relevant, with time as fixed effect and patient as random effect. Anti-S titre was log-transformed to achieve normality. Analyses were performed using STATA software (release 16.0, Stata Corporation, College Station, TX).

3. Results

3.1. Baseline features

A total of 182 patients with cirrhosis and 38 healthy unmatched controls entered the study (Fig. 1) and were studied accordingly for humoral and T-cell response at pre-defined time-points (Fig. 2). Patients with cirrhosis had a median age of 61 (20–89) years and were predominantly males (75%). Detailed baseline demographic and clinical features are reported in Table 1. One hundred and thirty-five patients (74%) had a well-compensated cirrhosis (Child-Pugh A), 50 (31%) had a diagnosis of HCC (16 with active HCC). Among cirrhotic patients, 28 (16%) had a previous SARS-CoV-2 infection [20 symptomatic COVID-19, the median time elapsing between recovery and first dose of vaccine was 208 (26–432) days] and 154 (84%) were SARS-CoV-2 naïve. Between March and July 2021, 180 (99%) patients received 2 doses of COVID-19 mRNA vaccines: 119 (66%) BNT162b2 and 61 (34%) mRNA-1273; while 2 patients received a single dose of BNT162b2, because of recent history of COVID-19.

Baseline features of 38 healthy subjects (control group) vaccinated with mRNA-vaccines are presented in Table 1: 12 (31%) had previous exposure to SARS-CoV-2 (10 symptomatic COVID-19, the median time elapsing between recovery and first dose of vaccine was 258 (88–348) days) and 29 (76%) received BNT162b2 vaccine and 9 (24%) the mRNA-1273 one.

3.2. Humoral response (anti-S titres) at different time-points and predictors of response

After the first vaccine dose (V1), 102 (60%) patients with cirrhosis were positive for anti-S compared to 31 (97%) healthy controls (p<0.001), the median antibody titres being significantly lower in the former group [235 (0.4–25,000) U/mL vs 84.8 (0.4–25,500) U/mL, p = 0.0001]. Anti-S titres were significantly lower among SARS-CoV-2 naïve cirrhotics compared to those with previous SARS-CoV-2 infection 13.9 (0.4–14,336) U/mL vs 7500 (273–25,000) U/mL (p<0.001) and the same held true for healthy controls [43.1 (0.4–345) U/mL vs 17,300 (8962–25,000) U/mL (p<0.001)] (Fig. 3). Among 145 SARS-CoV-2 naïve patients, 76 (52%) resulted anti-S Ab positive after the first vaccine dose compared to 22 (96%) healthy SARS-CoV-2 naïve subjects (p<0.001), the median anti-S Ab titres were 13.9 (0.4–14,336) U/mL vs 43.1 (0.4–345) U/mL p = 0.001.

The primary endpoint of the study was humoral response 21 days after the second dose of vaccine (V2): 163 patients with cirrhosis resulted positive for anti-S (97%) compared to 33 healthy controls (100%) (p = 0.07), the anti-S titres being significantly lower in the former group [1751 (0.4–25,000) U/mL vs 4523 (259–25,000) U/mL, p = 0.012] (Fig. 3). Among 140 SARS-CoV-2 naïve patients, 135 (96%) were positive for anti-S after the second dose of vaccine compared to 22 (100%) healthy subjects (p = 0.10): the median anti-S titres were 999 (0.4–17,329) U/mL vs 1520 (259–13,500) U/mL, p = 0.05. Among patients with cirrhosis, anti-S titres were significantly lower in the SARS-CoV-2 naïve compared to those with previous SARS-CoV-2 infection [999 (0.4–17,329) U/mL vs 7500 (12.5–25,000) U/mL, (p<0.001)].

In SARS-CoV-2 naïve cirrhotics, independent baseline predictors of lower anti-S titres 21 days after the second dose of mRNA vacc-
ARTICLE IN PRESS

JID: YDLD [m5G;October 17, 2022;11:36]
M. Iavarone, G. Tosetti, F. Facchetti et al.  Digestive and Liver Disease xxx (xxxx) xxx

Fig. 2. Disposition of patients with cirrhosis and healthy controls over time and according to the previous SARS-CoV-2 exposure.

Table 1
Demographic and clinical characteristics of the 182 patients with cirrhosis and 38 healthy controls enrolled in the study.

| Characteristics                              | Patients (n = 182) | Healthy controls (n = 38) |
|----------------------------------------------|-------------------|--------------------------|
| Age, years                                   | 61 (20–89)        | 56 (29–73)               |
| Males                                        | 136 (75)          | 11 (29)                  |
| Ethnicity, Caucasian                         | 168 (92)          | 38 (100)                 |
| Etiology of liver disease                   |                   |                          |
| Viral*                                       | 82 (45)           |                          |
| Alcohol                                      | 26 (14)           |                          |
| Metabolic                                    | 14 (8)            |                          |
| Multiple                                     | 36 (20)           |                          |
| Other                                        | 24 (13)           |                          |
| Albumin, g/dl                                | 4.0 (2.5–4.0)     |                          |
| Bilirubin, mg/dl                             | 1.0 (0.2–12.0)    |                          |
| INR                                          | 1.1 (0.9–2.0)     |                          |
| Ascites                                      | 65 (36)           |                          |
| Encephalopathy                               | 25 (14)           |                          |
| Platelet count/mm³                           | 119,000 (24,000–389,000) | |
| White blood cell count/mm³                   | 5175 (1100–14,510) | |
| Creatinine, mg/dl                            | 0.8 (0.5–7.1)     |                          |
| Child-Pugh score A (5–6)                     | 135 (74)          |                          |
| B (7–9)                                      | 30 (16)           |                          |
| C (10–15)                                    | 17 (10)           |                          |
| MELD score                                   | 8 (6–24)          |                          |
| MELD score ≥15                               | 14 (8)            |                          |
| HCC                                          | 56 (31)           |                          |
| previous                                     | 26 (46)           |                          |
| active                                       | 30 (54)           |                          |
| Esophagogastroduodenal varices               |                   |                          |
| Absent                                       | 79 (44)           |                          |
| Small                                        | 37 (20)           |                          |
| Medium/Large                                 | 66 (36)           |                          |
| Enlisted for liver transplantation           | 27 (15)           |                          |
| BMI, kg/m²                                   | 26 (16–43)        |                          |
| Recent or current steroid therapy            | 9 (5)             |                          |
| Comorbidity                                  |                   |                          |
| Obesity                                      | 43 (24)           |                          |
| Diabetes                                     | 39 (21)           |                          |
| Arterial hypertension                        | 80 (44)           |                          |
| HIV infection                                | 2 (1)             |                          |
| Chronic kidney disease*                      | 5 (3)             |                          |
| Comorbidities ≥2                             | 45 (25)           |                          |
| Previous SARS-CoV-2 exposure (%)             | 28 (16)           | 12 (31)                  |
| Vaccine type (%)                             |                   |                          |
| mRNA-162b2 (Comirnaty, Pfizer BioNTech)      | 121 (66)          | 29 (76)                  |
| mRNA-1273 (Spikevax, Moderna)                | 61 (34)           | 9 (24)                   |

Values are reported as n (%) or median (range). INR, international normalized ratio; MELD, model for end-stage liver disease; HCC, hepatocellular carcinoma; BMI, body mass index; COVID-19, coronavirus disease 2019. *All patients but three with HCV achieved a sustained virological response and all patients with HBV were on effective nucleotide analogue therapy. **One patient in dialytic treatment. ***Comorbidities ≥2 were diabetes, obesity, arterial hypertension, chronic bronchopneumopathies; chronic kidney disease, HIV.
cines (V2, Table 2) were Child-Pugh B/C, active HCC, and BNT162b2 vaccine. Based on this model, we compared anti-S titres of SARS-CoV-2 in naïve cirrhotics with either Child-Pugh B/C or active HCC with healthy naïve subjects: 632 (0.4–13,547) and 538 (0.04–5766) U/mL and vs 1520 (259–13,500) U/mL, p<0.001 and p = 0.002, respectively. While Child-Pugh A or HCC negative patients reached similar levels of anti-S Ab compared to healthy subjects at V2 [1377 (0.4–17,329) p = 0.179 and 1173 (0.4–17,329) p = 0.178, respectively].

When humoral responses after the first dose of vaccine (V1) were included in a time-related prediction model, independent predictors were active HCC, immunocompromised conditions, BNT162b2 vaccine and lower anti-S titres at V1 (Supplementary Table 1).

Another secondary endpoint was the kinetics of humoral response at different timepoints: the anti-S titres were significantly lower at the second (V3) compared to the first timepoint (V2); 657 (0.4–25,000) vs 1751 (0.4–25,000) U/mL, p<0.001 [median time elapsed from V2 to V3 111 (91–171) days]. In details, SARS-CoV-2 naïve patients with cirrhosis anti-S titres were significantly higher at V2 [999 (0.4–17,329) U/mL] compared to both V1 [139 (0.4–14,336) U/mL] and V3 [528 (0.4–8777)] [p<0.001 and p<0.001, respectively]. In patients with previous SARS-CoV-2 infection, similar anti-S titres were observed in the three time-points. The trend
over time of antibodies titres for both patients and controls at different time points is presented in Fig. 3. The proportion of patients with anti-S titres above the threshold considered protective (i.e. ≥100 U/mL) was 29%, 89% and 87% at V1, V2 and V3 in the overall patients’ population and 17%, 88% and 85%, among the SARS-CoV-2 naïve ones.

Considering both SARS-CoV-2 naïve and experienced patients, independent predictors of lower anti-S titres at V3 (median time 133 days from the second dose) were SARS-CoV-2 naïve condition and infection and BNT162b2 vaccine (Supplementary Table 2).

Among SARS-CoV-2 naïve patients, the response to vaccine at different time-points have been also reported in Fig. 4, according to Child-Pugh class, MELD score and presence of active HCC (Supplementary Table 3). The clinical characteristics of the 5 (%) patients who tested negative for anti-S Ab after two doses of vaccine are presented in Supplementary Table 4.

Among the 20 patients with previous symptomatic SARS-CoV-2 infection, the median anti-S titres were 277 (19.4–3422) U/mL at V0, 7500 (273–25,000) U/mL at V1, 7500 (7500–25,000) U/mL at V2 and 13,227 (1936–25,000) U/mL at V3; among the 8 patients with previous asymptomatic SARS-CoV-2 infection, the median anti-S titres were: 311 (45.5–781) U/mL at V0, 7500 (7500–10,187) U/mL at V1, 7500 (12.5–7500) U/mL at V2 and 12,880 (3471–25,000) U/mL at V3.

3.3. Spike-specific T cellular response

The kinetics of Spike-specific T-cell immune responses induced by two doses of mRNA vaccines was assessed in a subset of 25 patients with cirrhosis: median age was 63 (48–81) years; 72% were males, 68% with viral etiology, 72% with Child-Pugh A cirrhosis and 12% had experienced a previous SARS-CoV-2 infection.

The ability of mRNA vaccination to induce Spike-specific T-cells in cirrhotic patients was compared with the one obtained in 29 matched healthy controls (Fig. 5a). Vaccination induced Spike-specific T-cell response in all cirrhotic patients, but the kinetics of expansion and contraction of Spike-specific cytokines production was different to what observed in healthy controls. First and second doses of vaccine induced a quantity of Spike peptide pool induced T-cell cytokines inferior to what detected in healthy individuals, although not statistically significant. While the level of INF-gamma and IL-2 peptide induced cytokines in healthy controls was stable at day 60 and slightly decreased at V3, cirrhotic patients displayed a different kinetic of the T-cell response with delayed response with similar levels of INF-gamma and IL-2 production at day 133. The three cirrhotic patients who were vaccinated after an episode of SARS-CoV-2 infection, displayed a level of Spike-specific T-cell response that was higher than the one detected in cirrhotic naïve. Different kinetics according to previous infection and degree of liver decompensation are exemplified in Fig. 5B.

Among the 25 patients with available data for both SARS-CoV-2–specific T-cell -mediated and antibody responses elicited by mRNA vaccines, a statistically significant positive correlation between the anti-S titres and INF-gamma levels were found both at V2 (Spearman’s rho, 0.510 p = 0.0026) and V3 (Spearman’s rho, 0.435, p = 0.0025).

3.4. Post-vaccination infection rate

After a median follow-up of 4.8 (1.5–5.8) months since the first dose of vaccine, 4 cirrhotic patients turned anti-N positive (2%). One patient had a pauci-symptomatic COVID-19 after 2 doses of vaccine (fever and anosmia with PCR nasopharyngeal swab for SARS-CoV-2 positive) while the other 3 patients reported no symptoms related to infection. No patient was hospitalized for COVID-19. The anti-S titres at V2 (3.9 ± 0.6 months before anti-N positivity) were 8637, 7500 and 7500 U/mL in the three asymptomatic patients and 2665 U/mL in the pauci-symptomatic one, respectively.

3.5. Adverse events and clinical outcomes

No serious and unexpected adverse events were reported in patients with cirrhosis (Table 3). During the study period, 9 patients were liver transplanted (5 for end-stage liver disease and 4 for HCC): two patients with 1 dose only before transplant, while 7 patients were fully vaccinated with median time interval between second dose and transplant of 102 (3–202) days. Finally, 3 patients died (2 for end-stage liver disease and 1 for HCC progression); none with COVID-19-related symptoms.

4. Discussion

In this prospective study, we evaluated both humoral and T-cell spike-specific response at different time-points, incidence of breakthrough infections after vaccination and safety of COVID-19 mRNA vaccines in patients with compensated and decompensated cirrhosis with different aetiologies, compared to healthy subjects. We demonstrated that patients with cirrhosis had lower titres of anti-S compared to healthy controls and this was more evident in SARS-CoV-2 naïve patients with either a decompensated cirrhosis or an active HCC. Vaccination-induced spike-specific T-cell responses appeared slow but similar to healthy controls. Finally, in the 4 months following the second dose, there were a limited number of breakthrough infections; mRNA SARS-CoV-2 vaccines were well tolerated with no unexpected or severe adverse events.

**Fig. 4.** Humoral response to SARS-CoV-2 vaccination at different time-points (V1, V2 and V3) in SARS-CoV-2-naïve cirrhotics, stratified according to different conditions: panel A: patients with Child-Pugh class A vs B/C [at V2: 1377 (0.4–17,329) vs 632 (0.4–13,547)]; panel B: patients with MELD<15 vs MELD≥15 [at V2: 1116 (0.4–17,329) vs 692 (0.4–7500)]; panel C: patients with active HCC vs negative/previous HCC [at V2: 538 (0.4–5766 vs 1377 (0.4–17,329)]. Statistical analysis by Kruskal-Wallis Test.
The current knowledge on the long-term humoral response to vaccination in patients with cirrhosis is hampered by the fact that previous studies analysed only a single time-point after a full cycle of vaccination [13,14,18]. In contrast, in our study, we were able to assess the kinetics of humoral response over time, i.e. at three different time-points up to 133 days, comparing these findings in healthy controls and patients with different liver disease severity.

We observed a weaker response in SARS-CoV-2-naïve patients after the first dose as compared to both controls in the same conditions and patients with a previous SARS-CoV-2 exposure. Moreover, a waning antibody’s response was observed in SARS-CoV-2-naïve patients with cirrhosis, with a statistically significant decrease from the V2 to the V3 values, while patients with previous SARS-CoV-2 infection maintained high anti-S titres throughout the study pe-
riod, which could not be described in previous studies, while similar results have been recently shown in liver transplanted patients [13,14,18,19].

Since previous studies had either excluded patients with a known history of COVID-19 or did not screen patients for anti-N at baseline, our study is the first describing response to anti-COVID-19 vaccination in both patients and healthy controls with and without a previous SARS-CoV-2 exposure, without relying on symptoms but on anti-N positivity to rule out previous asymptomatic exposure. We have shown that, in patients with previous SARS-CoV-2 infection, titres of anti-S were comparable to those observed in healthy individuals, thus confirming also in cirrhotics that the “hybrid immunity” (infection and vaccination) grants for a rapid and durable protection against SARS-CoV-2. Ruether et al. tested 2 cirrhotic patients with a past symptomatic COVID-19, showing very high anti-S titres following the two doses of COVID-19 mRNA vaccine, similar to those obtained in healthy controls [18]. These data might also suggest an enhanced immunological response even in cirrhotics following booster vaccination [20,21].

Among SARS-CoV-2-naive patients with cirrhosis, who had in general a lower humoral response to vaccine compared to healthy individuals, those staged Child-Pugh B/C, with active HCC or immunization with mRNA BNT162b2 had lower anti-S titres after two doses of COVID-19 vaccine, according to the multivariable analysis with baseline variables only. In a second model which include also anti-S titres at V1 in a time-dependent mode, immunocompromised conditions and lower anti-S titres following the first dose emerged as other independent predictors of lower anti-S titres at V2. Previous studies excluded any statistically significant difference in terms of humoral (and T-cell response) in patients with compensated cirrhosis compared to those with a more advanced disease [13,14,18]. Thuluvath reported an “adequate response” >77% of 79 patients with cirrhosis, independently of disease severity [13].

At described similar humoral response in 11 Child-Pugh B/C compared to 142 Child-Pugh A patients following inactivated whole-virion vaccines [14]. Evaluations of the differences in immunogenicity between the mRNA vaccines are limited, however our results are in line with previous studies in general population reporting that SARS-CoV-2 anti-spike levels were significantly higher with mRNA-1273 than with BNT162b2 at 6–10 weeks after 2-dose vaccination [22]. Long-term response was independently predicted by previous SARS-CoV-2 infection and immunization by mRNA-1273 vaccine.

As a unique feature of our study in patients with cirrhosis, T-cell Spike-specific response was evaluated in a subgroup of patients and controls. Vaccination induced Spike-specific T-cell responses in all cirrhotic patients, but the kinetic of expansion and contraction was different to the one detected in healthy controls. Despite the level of Spike-specific T-cell response before vaccination was superior in cirrhotic than healthy individuals (likely due to the presence of T-cells cross-reactive to other Coronavirus) [23,24], first and second dose vaccination induce a quantity of Spike specific T-cell response inferior to what detected in healthy individuals. While Spike-specific T-cell response in healthy controls was stable at day 60 and slightly reduced at day 133, cirrhotic patients displayed a different kinetic of the T-cell response with slower growth reaching similar IFN-gamma and IL-2 production at day 133. These data, generated in a small proportion of patients with a few with decompensated cirrhosis, should be confirmed in larger cohort of patient. Of note, in the three SARS-CoV-2 experienced cirrhotics the level of Spike-specific T-cell response was superior to the one detected in naïve patients, showing that also in cirrhosis heterologous immunity elicits a superior level of antiviral immunity than vaccination alone [20,21].

At the time of reporting, the proportion of patients who seroconverted to anti-N was quite low, only 2%. Moreover, these few patients remained fully asymptomatic or developed mild symptoms. The only and largest study on breakthrough infection in patients with cirrhosis after anti-COVID-19 vaccination reported a reduced risk of death by multivariable analysis of a 1:2 propensity matched US cohort including vaccinated and unvaccinated patients [25]. However, in this retrospective study patients were not tested for humoral response to vaccines, thus limiting the comparability to our study.

Safety remains an important endpoint of any study in which patients with severe liver disease are enrolled: no serious safety signals were reported in our patients and hence we suggest continuing vaccination of our patients, even with the third dose. Similar data has been previously shown in patients chronic liver disease with inactivated whole-virion SARS-CoV-2 vaccination [14].

We acknowledge that the current study has some limitations. First, these are preliminary results with a follow-up limited to 4 months. Larger multicenter studies are deemed necessary to define the added value of the third dose of vaccine, as currently recommended in Italy and worldwide. Secondly, the number of patients enrolled in the study, and those analyzed for T-cell responses is limited and data on long-term cellular response is lacking, thus deserving further and larger studies to confirm our findings. Third, we do not have long term follow-up data on antibody titers for healthy controls. The fact that this first data-analysis was conducted both before the fourth wave of pandemic and before the third dose of anti-SARS-CoV-2 vaccine, favored a simplified and clearer analysis of the results which otherwise would be made extremely heterogeneous by the timing of the third dose together with any silent or paucisymptomatic infections, making the results more difficult to interpret. Moreover, this is the first study including both patients and controls, SARS-CoV-2-naive and experienced subjects, and multiple samples collection to study both humoral and cellular responses, thus giving the most comprehensive view to date published in vaccinated patients with cirrhosis. Finally, the number of patients with breakthrough infection might be underestimated in other studies because asymptomatic patients might be less likely to report to medical attention and undergo testing. In our study we were able to detect all seroconversion independently on symptoms of COVID-19, thanks to the design of the study itself which provided for the evaluation of anti-N at pre-established time-points.

In conclusion, this study demonstrates that COVID-19 mRNA vaccination is safe in patients with cirrhosis but elicits weaker humoral and slower cellular responses compared to healthy subjects, particularly in SARS-CoV-2-naive cirrhetics with decompensated cirrhosis and active HCC. These patients should be counselled to follow self-protective behavior to minimize the risk of infection, since post-vaccination COVID-19 in patients with cirrhosis maintains a residual risk of serious outcomes [25].

**Conflict of interest**

MI: Speaking/Teaching, consultant and advisory board for Bayer, Gilead Sciences, BMS, Janssen, Ipsen, MSD, BTG-Boston Scientific, AbbVie, Guerbet, EISAI, Roche.

BA: A patent for a method to monitor SARS-CoV-2-specific T-cells in biological samples pending.

PL: Advisory Board/Speaker Bureau for BMS, ROCHE, GILEAD SCIENCES, GSK, ABBVIE, MSD, ARROWHEAD, ALNYLAM, JANSSEN, SBRING BANK, MYR, EIGER, ALIGOS, ANTIOS, VIR.

**Funding**

The study was funded in part by the following grants: Italian Ministry of Health (“Ricerca Corrente KC2021/105-1”), National Research Foundation (NRF-000230-00; NRF-CRP25-2020-0003). Sin-
gapore Ministry of Health’s National Medical Research Council MOH-000019 (MOHStaR7Nov-0001).

Acknowledgments

Mss A Arbia and Mrs D Dessi for administrative assistance.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.dld.2022.09.010.

References

[1] Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2021;19:141–54.
[2] Iavarone A, D’Ambrosio R, Soria A, et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol 2020;73:1063–71.
[3] Marjot T, Moon AM, Cook JA, et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. J Hepatol 2021;74:567–77.
[4] Kim D, Adeniji N, Latt N, et al. Predictors of outcomes of COVID-19 in patients with chronic liver disease: US Multi-center Study. Clin Gastroenterol Hepatol 2021;19:1469–79.
[5] Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603–15.
[6] Voysey M, Clemens SAC, Madhu SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99–111.
[7] Baden LR, El Sahly HM, Essink B, et al. COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403–16.
[8] Fix OK, Blumberg EA, Chang KM, et al. American Association for the Study of Liver Diseases Expert Panel Consensus Statement: vaccines to prevent coronavirus disease 2019 infection in patients with liver disease. Hepatology 2021;74:1049–64.
[9] Cornberg M, Buti M, Eberhardt CS, et al. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. J Hepatol 2021;74:944–51.
[10] McCashland TM, Preheim LC, Gentry MJ. Pneumococcal vaccine response in cirrhosis and liver transplantation. J Infect Dis 2000;181:757–60.
[11] Ageletopoulou I, Davoulou P, Konstantakis C, et al. Response to hepatitis B vaccination in patients with liver cirrhosis. Rev Med Virol 2017;27:e1942.
[12] Hämälä A, Parisinos CA, Shallicross L, et al. Effectiveness of influenza vaccines in adults with chronic liver disease: a systematic review and meta-analysis. BMJ Open 2019;9:e031070.
[13] Thuluvath PJ, Roberts P, Chauhan M. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases. J Hepatol 2021;75:1434–9.
[14] Wang J, Hou Z, Liu J, et al. Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): a multicenter study. J Hepatol 2021;75:439–49.
[15] Xiang T, Liang B, Wang H, et al. Safety and immunogenicity of a SARS-CoV-2 inactivated vaccine in patients with chronic hepatitis B virus infection. Cell Mol Immunol 2021;18:2679–81.
[16] Tan AT, Lim JM, Le Bert N, et al. Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals. J Clin Invest 2021;131:e152379.
[17] Le Bert N, Clapham HE, Tan AT, et al. Highly functional virus-specific specific-cellular immune response in asymptomatic SARS-CoV-2 infection. J Exp Med 2021;218:e20202817.
[18] Rueder DF, Schaub GM, Duengelhoef PM, et al. SARS-CoV2-specific humoral and T-cell immune response after second vaccination in liver cirrhosis and transplant patients. Clin Gastroenterol Hepatol 2022;20:162–72.
[19] Toniutto P, Falletti E, Cemt S, et al. Past COVID-19 and immunosuppressive regimen affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients. J Hepatol 2022.
[20] Goel RR, Painter MM, Apostolidis SA, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 2021;374:abm8029.
[21] Lozano-Ojaval D, Camara C, Lopez-Granados E, et al. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals. Cell Rep 2021;36:109570.
[22] Steensels D, Piertet N, Penders J, et al. Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273. JAMA 2021;326:1533–5.
[23] Raun J, Loyal I, Frensch M, et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature 2020;587:270–4.
[24] Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 2020;584:457–62.
[25] John BV, Deng Y, Schwartz KB, et al. Post-vaccination COVID-19 infection is associated with reduced mortality in patients with cirrhosis. Hepatology 2022 Epub ahead of print. PMID: 35023206. doi: 10.1002/hep.32337.